DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

To achieve truly patient-centered drug development, we must understand, measure, and communicate therapeutic benefit from the patient’s perspective. Only by understanding the outcomes that are most important to patients and their caregivers can sponsors to develop patient-centered outcome assessment strategies for clinical trials and real world studies.”

As Technical Lead in Clinical Outcomes Assessment, Helen provides strategic input on measurement strategy and patient outcomes research. Helen has worked in outcomes research for over 8 years and has developed and validated COAs including patient-reported outcome (PRO) and clinician-reported outcome (ClinROs) measures for clinical trials and clinical practice. Helen has experience across a range of therapy areas and specializes in qualitative, quantitative, and mixed methods research including innovative patient-centered research methods. Helen previously held academic research posts at the University of Manchester and spent 4 years in consulting with Adelphi (Mapi) Values.  Helen is an active member of the International Society for Quality of Life Research (ISOQOL) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) participating in symposiums, special interest groups, and as an invitational abstract reviewer. Helen holds an MSc (Merit) in Health Psychology from Sheffield Hallam University and a BA(Hons) in Psychology from the University of Manchester.